Weight-loss medications work only while patients keep taking them. The real goal is staying on medication long enough to achieve meaningful, functional weight loss and sustain it. This webinar explores why that’s harder than it sounds: not for the clinical reasons often expected, but rather because of the beliefs and psychology, including the significance of volitional medication use in obesity, that predict who stays engaged and who drops off before seeing the long-term benefits.
For pharma professionals supporting an obesity portfolio, that gap is an important challenge to address. Clinical trials show sustained weight reduction of 15–22% over 72 weeks, but real-world discontinuation can be up to 67% within 12 months. Side effects, cost and access explain only part of that drop-off. Most support programs have no validated way to identify behavioral risk before it impacts success.
Psychological factors, such as confidence, doubt and treatment identity, are increasingly recognized as independent predictors of discontinuation. Underlying motivations and beliefs about treatment, whether rooted in appearance, day-to-day function or long-term health risk, differ from patient to patient. Left unaddressed, these differences can determine whether someone stays on treatment and reaches a functional, lasting outcome. Digital health technology can help keep people engaged and on track.
The featured speakers will discuss findings from a novel study of 1,056 US adults using a GLP-1/GIP medication for weight management, evaluated using the SPUR behavioral framework alongside validated belief and mental-health measures. They’ll introduce Kaitality™, Clinical ink’s general wellness app, and show how connecting biometrics (weight, body composition and activity), sociometrics (social context and daily environment) and psychometrics (validated psychological drivers of adherence) can generate real-world evidence and support progress toward sustained functional quality weight loss goals.
Register for this webinar to learn how a behavioral profile can help identify adherence risk, personalize patient support and support sustained functional weight loss.
Speakers
Christian Djurhuus, MD, PhD, EVP Disease Management, Chief Scientific Officer, Clinical ink
Dr. Christian Born Djurhuus brings nearly three decades of experience in cardiometabolic drug development and digital transformation. In his capacity as CSO, Dr. Djurhuus focuses on advancing Clinical Ink’s industry leading offerings supporting cardiometabolic drug development. In his role as EVP, Disease Management, he oversees the creation and delivery of disease management and health management products designed to support patients receiving FDA approved therapies, while strengthening evidence generation for biopharma partners.
Prior to joining Clinical ink, Dr. Djurhuus held multiple senior leadership roles at Novo Nordisk. Most recently, he served as Corporate Vice President, Process Transformation & Digitalization, Global Trial Portfolio, where he was responsible for decentralized clinical trial strategies and patient facing technologies. He previously served as Chief Digital Officer and as Vice President of Medical Science, with responsibility for global development programs in the cardiometabolic therapeutic area.
Dr. Djurhuus holds an MD in Medicine and a PhD in Endocrinology and Metabolism from the University of Aarhus, as well as a Bachelor of Science in Informatics. His background uniquely combines deep scientific expertise with digital innovation, enabling him to advance solutions that deliver meaningful impact for patients and sponsors alike.
Message Presenter
Nicholas Alp, MD, PhD, FACC Chief Medical Officer, Clinical ink
Nicholas Alp has more than 30 years of clinical research experience as an academic Cardiologist, Clinical Trialist and Commercial Drug Development Expert. Before joining Clinical ink, he was Senior Vice President and Head of Cardiometabolic Research at Medpace, a global clinical research organization. Previously, Nicholas was Vice President and Global Head of Cardiovascular Drug Development at ICON. He also held appointments as a Consultant Interventional Cardiologist at the John Radcliffe Hospital, Oxford and a senior academic appointment in Cardiovascular Medicine at Oxford University.
Nicholas trained in Medicine at London University and Oxford University, completed a PhD in Immunology at Cambridge University, with a further Post-Doctoral DM degree in Cardiology at Oxford University. He has also contributed to more than 70 peer-reviewed publications and books.
Message Presenter
(Moderator) Bob DiLuzio, Senior Vice President, Disease Management, Clinical ink
Bob DeLuzio brings more than 30 years of life sciences experience across commercially focused roles in pharma sales, technology and data. He has led global sales teams and helped customers achieve their objectives by aligning the people, products and services he represented with the outcomes they were trying to achieve. In his current role, he is supporting the launch of Clinical Ink’s Disease Management Business Unit, with responsibility for business development, commercial strategy and go-to-market leadership.
Before joining Clinical Ink, Bob held account and sales leadership roles at Veeva, Oracle and IMS Health. He began his career supporting the launch and market success of numerous drug compounds while at Pfizer and Parke-Davis.
Message PresenterWho Should Attend?
This webinar will appeal to pharma medical, marketing and real-world evidence professionals supporting obesity portfolios including:
- Medical Affairs and Outcomes Research / HEOR professionals evaluating real-world evidence strategies for GLP-1 and obesity portfolios
- Digital Health leads (clinical and commercial) assessing behavioral and biometric technology partnerships
- Brand team leads responsible for brand strategy and performance from launch through lifecycle
- Patient Support Program (PSP) leaders looking for predictive, behavioral-driven adherence support to help people meet and maintain their weight loss goals
- Pharma Commercial and Market Research teams tracking the evolving GLP-1 competitive and adherence landscape
What You Will Learn
Attendees will learn:
- How connecting behavioral profiles with objective biometric data can help support programs prioritize outreach before disengagement
- How behavioral and biometric data can inform more personalized patient support
- How behavioral drivers can help explain treatment continuation beyond factors such as side effects, cost and access
- How support programs can move beyond pounds lost toward sustained, functional quality weight loss
- How behavioral insights can inform patient adherence programs, shape real-world evidence strategy or manage GLP-1-related health outcomes
Xtalks Partner
Clinical ink
Clinical ink is a global life science company bringing data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, behavioral and dropout prediction, eConsent, telehealth, and digital biomarkers advancements, including use of Continuous Glucose Monitoring for detection of hypoglycemia, support the next generation of clinical trials and ultimately the clinical management of patients.
The Disease Management business unit leverages the eCOA, validated behavioral science, and connected device technology extended to serve the digital health technology commercial market. This expands Clinical ink’s focus to also include health and disease management for people receiving FDA approved medicines. Kaitality™ is the initial Digital Health Technology app developed by the Disease Management team.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account